
Bruker Corporation
NASDAQ•BRKR
CEO: Dr. Frank H. Laukien Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2000-08-04
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Contact Information
Market Cap
$5.87B
P/E (TTM)
73.7
vs Industry 42.6
Dividend Yield (TTM)
0.5%
52W High
$64.64
52W Low
$28.53
52W Range
5.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q2 2025 Data
Revenue
$797.40M-0.41%
4-Quarter Trend
EPS
$0.05-3.10%
4-Quarter Trend
FCF
-$148.80M+533.19%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
$4.89B
BRKR$3.44B
$3.04B
Gross Margin (Latest Quarter)
KRYS90.9%
TGTX86.6%
GKOS78.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| BRKR | $5.87B | 73.7 | 4.4% | 38.4% |
| IRTC | $5.87B | -62.4 | -104.7% | 76.2% |
| PCVX | $5.79B | -11.1 | -16.9% | 2.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
-2.7%
Flat Growth
4-Quarter Net Income CAGR
-42.9%
Declining Profitability
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Reports
All Years
Form 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $797.40M-0.4%|EPS: $0.05-3.1%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 7, 2025|Revenue: $801.40M+11.0%|EPS: $0.11-68.6%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 3, 2025|Revenue: $3.37B+13.6%|EPS: $0.76-74.0%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 7, 2024|Revenue: $864.40M+16.4%|EPS: $0.28-53.3%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 9, 2024|Revenue: $800.70M+17.4%|EPS: $0.05-86.8%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 10, 2024|Revenue: $721.70M+5.3%|EPS: $0.35-32.7%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 29, 2024|Revenue: $2.96B+17.1%|EPS: $2.92+46.0%BeatForm 10-Q - Q3 2023
Period End: Sep 30, 2023|Filed: Nov 9, 2023|Revenue: $742.80M+16.3%|EPS: $0.60+0.0%Miss